Comparative Pharmacology
Head-to-head clinical analysis: POMALIDOMIDE versus THALOMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POMALIDOMIDE versus THALOMID.
POMALIDOMIDE vs THALOMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
Thalidomide is an immunomodulatory agent with antiangiogenic and anti-inflammatory properties. Its exact mechanism is not fully understood, but it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine activity, and suppresses angiogenesis by inhibiting basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
200 mg orally once daily, taken with water preferably at bedtime to reduce sedation; dose may be titrated up to 400 mg daily based on tolerability.
None Documented
None Documented
Clinical Note
moderatePomalidomide + Digoxin
"Pomalidomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePomalidomide + Digitoxin
"Pomalidomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePomalidomide + Deslanoside
"Pomalidomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePomalidomide + Acetyldigitoxin
"Pomalidomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
Mean terminal elimination half-life is approximately 5-7 hours in healthy adults; may be prolonged to 12-18 hours in patients with hepatic impairment due to decreased metabolism.
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
Primarily renal: >80% of absorbed dose excreted unchanged in urine. Minor fecal elimination (<15%). No significant biliary excretion.
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent